Gluconorm-VG 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, reducing postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, promoting consistent plasma concentrations and improving patient compliance by reducing dosing frequency. Gluconorm-VG 2 is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve target glycemic levels. It is essential to monitor blood glucose regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe infections. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare allergic reactions. This combination therapy offers a multifaceted approach to managing type 2 diabetes by targeting different pathophysiological mechanisms.